Skip to main content

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 1 of 12

  1. Evidence bearing on the role of statins in the prevention and treatment of cancer is confounded by the diversity of statins, chemotherapeutic agents and cancer types included in the numerous published studies;...

    Authors: Kaitlyn A. Khandelwal Gilman, Seungmin Han, Young-Wook Won and Charles W. Putnam

    Citation: BMC Cancer 2021 21:356

    Content type: Research article

    Published on:

  2. We prepared an anti-p21Ras scFv which could specifically bind with mutant and wild-type p21Ras. However, it cannot penetrate the cell membrane, which prevents it from binding to p21Ras in the cytoplasm. Here, ...

    Authors: Chen-Chen Huang, Fang-Rui Liu, Qiang Feng, Xin-Yan Pan, Shu-Ling Song and Ju-Lun Yang

    Citation: BMC Cancer 2021 21:321

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Cancer 2021 21:361

  3. Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRA D842V-mutant gastrointestinal stromal ...

    Authors: Margaret von Mehren, Michael C. Heinrich, Hongliang Shi, Sergio Iannazzo, Raymond Mankoski, Saša Dimitrijević, Gerard Hoehn, Silvia Chiroli and Suzanne George

    Citation: BMC Cancer 2021 21:291

    Content type: Research article

    Published on:

  4. Epidermal growth factor receptor (EGFR) is a target for cancer therapy as it is overexpressed in a wide variety of cancers. Therapeutic antibodies that bind EGFR are being evaluated in clinical trials as imagi...

    Authors: Wendy Bernhard, Kris Barreto, Ayman El-Sayed, Carolina Gonzalez, Raja Solomon Viswas, Darien Toledo, Angel Casaco, John DeCoteau, Humphrey Fonge and Clarence Ronald Geyer

    Citation: BMC Cancer 2021 21:270

    Content type: Research article

    Published on:

  5. Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antib...

    Authors: Fumihiko Matsuzawa, Hirofumi Kamachi, Tatsuzo Mizukami, Takahiro Einama, Futoshi Kawamata, Yuki Fujii, Moto Fukai, Nozomi Kobayashi, Yutaka Hatanaka and Akinobu Taketomi

    Citation: BMC Cancer 2021 21:200

    Content type: Research article

    Published on:

  6. The concept of personalized therapy has been proven to be a promising approach. A popular technique is to utilize gold nanoparticles (AuNPs) as drug delivery vectors for cytotoxic drugs and small molecule inhi...

    Authors: Hend M. Abdel Hamid, Zeinab E. Darwish, Sahar M. Elsheikh, Ghada M. Mourad, Hanaa M. Donia and Marwa M. Afifi

    Citation: BMC Cancer 2021 21:170

    Content type: Research article

    Published on:

  7. Side population (SP) cells, which have similar features to those of cancer stem cells, show resistance to dexamethasone (Dex) treatment. Thus, new drugs that can be used in combination with Dex to reduce the p...

    Authors: Wenfeng He, Yonghui Fu, Yongliang Zheng, Xiaoping Wang, Bin Liu and Junquan Zeng

    Citation: BMC Cancer 2021 21:125

    Content type: Research article

    Published on:

  9. Chemoresistance is one of the main problems in treatment of cancer. Periostin (PN) is a stromal protein which is mostly secreted from cancer associated fibroblasts in the tumor microenvironment and can promote...

    Authors: Khine Kyaw Oo, Thanpawee Kamolhan, Anish Soni, Suyanee Thongchot, Chalermchai Mitrpant, Pornchai O-charoenrat, Chanitra Thuwajit and Peti Thuwajit

    Citation: BMC Cancer 2021 21:65

    Content type: Research article

    Published on:

  10. Neoadjuvant chemotherapy (NACT) is the prime approach to the management of locally advanced breast cancer (LABC). Influenced by different factors such as pathologic tumor characteristics, hormone receptor stat...

    Authors: Dena Firouzabadi, Amirreza Dehghanian, Alireza Rezvani, Laleh Mahmoudi and Abdolrasoul Talei

    Citation: BMC Cancer 2021 21:47

    Content type: Research article

    Published on:

  11. Rho-family GTPases, including Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division control protein 42 (Cdc42), are important modulators of cancer-relevant cell functions and are viewed as promis...

    Authors: Martha M. Grimes, S. Ray Kenney, Dayna R. Dominguez, Kathryn J. Brayer, Yuna Guo, Angela Wandinger-Ness and Laurie G. Hudson

    Citation: BMC Cancer 2021 21:40

    Content type: Research article

    Published on:

  12. Our previous studies demonstrated that the administration of crude Polysaccharide from Panax notoginseng (CPPN) can effectively prolong the lifespan of tumor-bearing mice via boosting the host immune system as we...

    Authors: Yan-Hong Liu, Hua-Yan Qin, Yuan-Yuan Zhong, Shuang Li, Hua-Jing Wang, Hong Wang, Li-Ling Chen, Xiang Tang, Ya-Lin Li, Zhong-Yi Qian, Huai-Yu Li, Lei Zhang and Tong Chen

    Citation: BMC Cancer 2021 21:37

    Content type: Research article

    Published on:

  13. The continual reassessment method (CRM) identifies the maximum tolerated dose (MTD) more efficiently and identifies the true MTD more frequently compared to standard methods such as the 3 + 3 method. An initia...

    Authors: G. D. James, S. Symeonides, J. Marshall, J. Young and G. Clack

    Citation: BMC Cancer 2021 21:7

    Content type: Research article

    Published on:

  14. Glypican-1 is a heparan sulfate proteoglycan that is overexpressed in prostate cancer (PCa), and a variety of solid tumors. Importantly, expression is restricted in normal tissue, making it an ideal tumor targ...

    Authors: Maria E. Lund, Christopher B. Howard, Kristofer J. Thurecht, Douglas H. Campbell, Stephen M. Mahler and Bradley J. Walsh

    Citation: BMC Cancer 2020 20:1214

    Content type: Research article

    Published on:

  15. Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AM...

    Authors: Sook-Kyoung Heo, Eui-Kyu Noh, Ho-Min Yu, Do Kyoung Kim, Hye Jin Seo, Yoo Jin Lee, Jaekyung Cheon, Su Jin Koh, Young Joo Min, Yunsuk Choi and Jae-Cheol Jo

    Citation: BMC Cancer 2020 20:1193

    Content type: Research article

    Published on:

  16. The treatment of Ewing sarcoma, an aggressive bone and soft tissue sarcoma, is associated with suboptimal outcomes and significant side-effects. Consequently, there is an urgent need to identify novel therapie...

    Authors: Torin Waters, Kelli L. Goss, Stacia L. Koppenhafer, William W. Terry and David J. Gordon

    Citation: BMC Cancer 2020 20:1171

    Content type: Research article

    Published on:

  17. Preoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally advanced rectal cancer. The “Tratamiento de Tumores Digestivos” group (TTD) previously reported in a randomized ...

    Authors: Ramón Salazar, Jaume Capdevila, Jose Luis Manzano, Carles Pericay, Mercedes Martínez-Villacampa, Carlos López, Ferrán Losa, María José Safont, Auxiliadora Gómez-España, Vicente Alonso-Orduña, Pilar Escudero, Javier Gallego, Beatriz García-Paredes, Amalia Palacios, Sebastiano Biondo, Cristina Grávalos…

    Citation: BMC Cancer 2020 20:1164

    Content type: Research article

    Published on:

  18. Peritoneal metastasis (PM) in patients with breast (BC) and endometrial cancer (EC) is rare and treatment options are limited. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) has demonstrated efficacy...

    Authors: Günther A. Rezniczek, Urs Giger-Pabst, Omar Thaher and Clemens B. Tempfer

    Citation: BMC Cancer 2020 20:1122

    Content type: Research article

    Published on:

  19. Breast cancer (BC) is the second most common type of cancer worldwide. Among targeted therapies for Hormone Receptor-positive (HR+) and Human Epidermal growth factor Receptor 2-negative (HER2−) BC, the Cyclin-Dep...

    Authors: Oliviero Marinelli, Emanuela Romagnoli, Federica Maggi, Massimo Nabissi, Consuelo Amantini, Maria Beatrice Morelli, Matteo Santoni, Nicola Battelli and Giorgio Santoni

    Citation: BMC Cancer 2020 20:1119

    Content type: Research article

    Published on:

  20. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options. RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nu...

    Authors: John J. Tentler, Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young B. Lee, Andrew Eisen, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, Todd M. Pitts, Roberta Pelanda, S. Gail Eckhardt and Jennifer R. Diamond

    Citation: BMC Cancer 2020 20:1063

    Content type: Research article

    Published on:

  22. Hypoxic tumors are known to be highly resistant to radiotherapy and cause poor prognosis in non-small cell lung cancer (NSCLC) patients. CKD-516, a novel vascular disrupting agent (VDA), mainly affects blood v...

    Authors: Min-Young Kim, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Yeon Sil Kim, Chan Kwon Jung and Jin-Hyoung Kang

    Citation: BMC Cancer 2020 20:1057

    Content type: Research article

    Published on:

  23. Both intermittent intravenous (IIV) infusion and continuous intravenous (CIV) infusion of Endostar are widely used for NSCLC in China. We aimed to compare the efficacy and safety of CIV of Endostar versus IIV ...

    Authors: Bo Wang, Lu Xu, Qihuan Li, Sailimai Man, Cheng Jin, Lian Liu, Siyan Zhan and Yi Ning

    Citation: BMC Cancer 2020 20:1021

    Content type: Research article

    Published on:

  24. New treatment options for ovarian cancer are urgently required. Tumor-associated macrophages (TAMs) are an attractive target for therapy; repolarizing TAMs from M2 (pro-tumor) to M1 (anti-tumor) phenotypes rep...

    Authors: Alyssa A. Hoover, Demetra H. Hufnagel, Whitney Harris, Kennady Bullock, Evan B. Glass, Esther Liu, Whitney Barham, Marta A. Crispens, Dineo Khabele, Todd D. Giorgio, Andrew J. Wilson and Fiona E. Yull

    Citation: BMC Cancer 2020 20:970

    Content type: Research article

    Published on:

  25. Previous studies have shown a major green tea polyphenol (−)-epigallocatechin-3-gallate ((−)-EGCG) as a powerful anti-cancer agent. However, its poor bioavailability and requirement of a high dosage to manifes...

    Authors: Gene Chi Wai Man, Jianzhang Wang, Yi Song, Jack Ho Wong, Yu Zhao, Tat San Lau, Kam Tong Leung, Tak Hang Chan, Huating Wang, Joseph Kwong, Tzi Bun Ng and Chi Chiu Wang

    Citation: BMC Cancer 2020 20:964

    Content type: Research article

    Published on:

  26. Colorectal cancer (CRC) is the second most common cause of cancer-related mortality worldwide with one in every five patients diagnosed with metastatic CRC (mCRC). In mCRC cases, the 5-year survival rate remai...

    Authors: Susan A. Kennedy, Maria E. Morrissey, Margaret R. Dunne, Fiona O’Connell, Clare T. Butler, Mary-Clare Cathcart, Amy M. Buckley, Brian J. Mehigan, John O. Larkin, Paul McCormick, Breandán N. Kennedy and Jacintha O’Sullivan

    Citation: BMC Cancer 2020 20:952

    Content type: Research article

    Published on:

  28. Lung squamous cell carcinoma (LSCC) remains a challenging disease to treat, and further improvements in prognosis are dependent upon the identification of LSCC-specific therapeutic biomarkers and/or targets. W...

    Authors: Erkhem-Ochir Bilguun, Kyoichi Kaira, Reika Kawabata-Iwakawa, Susumu Rokudai, Kimihiro Shimizu, Takehiko Yokobori, Tetsunari Oyama, Ken Shirabe and Masahiko Nishiyama

    Citation: BMC Cancer 2020 20:935

    Content type: Research article

    Published on:

  29. Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of in...

    Authors: Amber Blaauboer, Stephanie Booy, Peter M. van Koetsveld, Bas Karels, Fadime Dogan, Suzanne van Zwienen, Casper H. J. van Eijck and Leo J. Hofland

    Citation: BMC Cancer 2020 20:913

    Content type: Research article

    Published on:

  30. A. oxyphylla extract is known to possess a wide range of pharmacological activites. However, the molecular mechanism of A. oxyphylla and its bioactive compound nootkatone in colorectal cancer is unknown.

    Authors: Eunsu Yoo, Jaehak Lee, Pattawika Lertpatipanpong, Junsun Ryu, Chong-Tai Kim, Eul-Yong Park and Seung Joon Baek

    Citation: BMC Cancer 2020 20:881

    Content type: Research article

    Published on:

  31. Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac are effective for colorectal cancer prevention in humans and some animal models, but concerns over gastro-intestinal (GI) ulceration ...

    Authors: Jennifer S. Davis, Preeti Kanikarla-Marie, Mihai Gagea, Patrick L. Yu, Dexing Fang, Manu Sebastian, Peiying Yang, Ernest Hawk, Roderick Dashwood, Lenard M. Lichtenberger, David Menter and Scott Kopetz

    Citation: BMC Cancer 2020 20:871

    Content type: Research article

    Published on:

  32. Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha...

    Authors: Elnaz Shirmohammadi, Seyed-Esmaeil Sadat Ebrahimi, Amir Farshchi and Mona Salimi

    Citation: BMC Cancer 2020 20:836

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Cancer 2020 20:1126

  34. Curcumin is herbal compound that has been shown to have anti-cancer effects in pre-clinical and clinical studies. The anti-cancer effects of curcumin include inhibiting the carcinogenesis, inhibiting angiogene...

    Authors: Kamran Mansouri, Shna Rasoulpoor, Alireza Daneshkhah, Soroush Abolfathi, Nader Salari, Masoud Mohammadi, Shabnam Rasoulpoor and Shervin Shabani

    Citation: BMC Cancer 2020 20:791

    Content type: Research article

    Published on:

  35. Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) which inhibits bindi...

    Authors: Jean-David Fumet, Emeric Limagne, Marion Thibaudin, Caroline Truntzer, Aurélie Bertaut, Emilie Rederstorff and Francois Ghiringhelli

    Citation: BMC Cancer 2020 20:748

    Content type: Study protocol

    Published on:

  36. Breast tumor initiating cells (BTIC) are stem-like cells that initiate and sustain tumor growth, and drive disease recurrence. Identifying therapies targeting BTIC has been hindered due primarily to their scar...

    Authors: William D. Gwynne, Mirza S. Shakeel, Adele Girgis-Gabardo, Kwang H. Kim, Emily Ford, Anna Dvorkin-Gheva, Craig Aarts, Methvin Isaac, Rima Al-awar and John A. Hassell

    Citation: BMC Cancer 2020 20:724

    Content type: Research article

    Published on:

  37. Colorectal cancer (CRC) is a heterogeneous tumor having various genetic alterations. The current treatment options had limited impact on disease free survival due to therapeutic resistance. Novel anticancer ag...

    Authors: Khayal Al-Khayal, Mansoor-Ali Vaali-Mohammed, Mohammed Elwatidy, Thamer Bin Traiki, Omar Al-Obeed, Mohammad Azam, Zahid Khan, Maha Abdulla and Rehan Ahmad

    Citation: BMC Cancer 2020 20:685

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Cancer 2020 20:834

  39. Tumors are heterogeneous in nature, composed of different cell populations with various mutations and/or phenotypes. Using a single drug to encounter cancer progression is generally ineffective. To improve the...

    Authors: Vanessa Bellat, Alice Verchère, Sally A. Ashe and Benedict Law

    Citation: BMC Cancer 2020 20:661

    Content type: Research article

    Published on:

  40. HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a n...

    Authors: Changjun Wang, Yan Lin, Yidong Zhou, Feng Mao, Hanjiang Zhu, Jinghong Guan, Xiaohui Zhang, Songjie Shen, Xin Huang, Chang Chen, Ru Yao, Jialin Zhao and Qiang Sun

    Citation: BMC Cancer 2020 20:653

    Content type: Study protocol

    Published on:

  41. Pancreatic cancer has a poor prognosis and few choices of therapy. For patients with adequate performance status, FOLFIRINOX or gemcitabine plus nab-paclitaxel are preferred first-line treatment. 5-Fluorouraci...

    Authors: Zev A. Wainberg, Kynan Feeney, Myung Ah Lee, Andrés Muñoz, Antonio Cubillo Gracián, Sara Lonardi, Baek-Yeol Ryoo, Annie Hung, Yong Lin, Johanna Bendell and J. Randolph Hecht

    Citation: BMC Cancer 2020 20:633

    Content type: Research article

    Published on:

  42. Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors (NETs) con...

    Authors: Linus D. Kloker, Susanne Berchtold, Irina Smirnow, Julia Beil, Andreas Krieg, Bence Sipos and Ulrich M. Lauer

    Citation: BMC Cancer 2020 20:628

    Content type: Research article

    Published on:

  43. Despite an improvement of prognosis in breast and colon cancer, the outcome of the metastatic disease is still severe. Microevolution of cancer cells often leads to drug resistance and tumor-recurrence. To tar...

    Authors: Jérôme Ruhnau, Jonas Parczyk, Kerstin Danker, Britta Eickholt and Andreas Klein

    Citation: BMC Cancer 2020 20:617

    Content type: Research article

    Published on:

  44. Modulated electro-hyperthermia (mEHT) is a form of hyperthermia used in cancer treatment. mEHT has demonstrated the ability to activate host immunity by inducing the release of heat shock proteins, triggering ...

    Authors: I-Ming Kuo, Jih-Jong Lee, Yu-Shan Wang, Hsin-Chien Chiang, Cheng-Chung Huang, Pei-Jong Hsieh, Winston Han, Chiao-Hsu Ke, Albert T. C. Liao and Chen-Si Lin

    Citation: BMC Cancer 2020 20:603

    Content type: Research article

    Published on:

  45. Unlike other breast cancer subtypes that may be treated with a variety of hormonal or targeted therapies, there is a need to identify new, effective targets for triple-negative breast cancer (TNBC). It has rec...

    Authors: Gina Sizemore, Sarah McLaughlin, Mackenzie Newman, Kathleen Brundage, Amanda Ammer, Karen Martin, Elena Pugacheva, James Coad, Malcolm D. Mattes and Han-Gang Yu

    Citation: BMC Cancer 2020 20:595

    Content type: Research article

    Published on:

  46. KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolyti...

    Authors: Ruwan Parakrama, Elisha Fogel, Carol Chandy, Titto Augustine, Matt Coffey, Lydia Tesfa, Sanjay Goel and Radhashree Maitra

    Citation: BMC Cancer 2020 20:569

    Content type: Research article

    Published on:

  47. It may be impossible to perform cancer surgery with free margins in the presence of an unresectable structure. Local drug treatment after surgery has been proposed to increase the rate of tumor control.

    Authors: Iman Al Dybiat, Alibi Baitukha, Cynthia Pimpie, Rachid Kaci, Marc Pocard, Farzaneh Arefi Khonsari and Massoud Mirshahi

    Citation: BMC Cancer 2020 20:565

    Content type: Research article

    Published on:

  48. Novel biomarkers are required to discern between breast tumors that should be targeted for treatment from those that would never become clinically apparent and/or life threatening for patients. Moreover, thera...

    Authors: Catharina Hagerling, Mark Owyong, Vaishnavi Sitarama, Chih-Yang Wang, Charlene Lin, Renske J. E. van den Bijgaart, Charlotte D. Koopman, Audrey Brenot, Ankitha Nanjaraj, Fredrik Wärnberg, Karin Jirström, Ophir D. Klein, Zena Werb and Vicki Plaks

    Citation: BMC Cancer 2020 20:542

    Content type: Research article

    Published on:

  49. Pediatric patients with relapsed or refractory disease represent a population with a desperate medical need. The aim of the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) program is to ...

    Authors: Cornelis M. van Tilburg, Ruth Witt, Melanie Heiss, Kristian W. Pajtler, Christoph Plass, Isabel Poschke, Michael Platten, Inga Harting, Oliver Sedlaczek, Angelika Freitag, David Meyrath, Lenka Taylor, Gnana Prakash Balasubramanian, Natalie Jäger, Elke Pfaff, Barbara C. Jones…

    Citation: BMC Cancer 2020 20:523

    Content type: Study protocol

    Published on:

  50. Glutamine serves as an important nutrient with many cancer types displaying glutamine dependence. Following cellular uptake glutamine is converted to glutamate in a reaction catalysed by mitochondrial glutamin...

    Authors: Dean C. Singleton, Anne-Lise Dechaume, Pamela M. Murray, William P. Katt, Bruce C. Baguley and Euphemia Y. Leung

    Citation: BMC Cancer 2020 20:470

    Content type: Research article

    Published on:

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us

\